Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | PDE9A | O76083 | 4/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502011 | 0.88 | MAPK1 (0.50) | MAPK1TYK2PDE9APDE1CMAPT | |
| SCHEMBL4514703 | 0.85 | PDE9A (0.55) | PDE9APDE1C | |
| SCHEMBL4515601 | 0.83 | MAPK1 (0.44) | MAPK1TYK2PDE9APDE1CMAPT | |
| SCHEMBL4591180 | 0.82 | TYK2 (0.62) | MAPK1TYK2MAPTCREBBPHSD17B10 | |
| SCHEMBL4504690 | 0.78 | TYK2 (0.49) | MAPK1TYK2HSD17B10ALDH1A1TSHR | |
| SCHEMBL4498181 | 0.75 | TYK2 (0.56) | MAPK1TYK2MAPTCREBBPHSD17B10 | |
| SCHEMBL4513101 | 0.75 | MAPK1 (0.51) | MAPK1TYK2PDE9AMAPTALDH1A1 | |
| SCHEMBL4510623 | 0.74 | TYK2 (0.55) | MAPK1TYK2MAPTCREBBPHSD17B10 | |
| SCHEMBL4516124 | 0.73 | TYK2 (0.54) | MAPK1TYK2PDE9APDE1CMAPT | |
| SCHEMBL17506173 | 0.73 | TYK2 (0.57) | MAPK1TYK2ALDH1A1TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | MAPK1 1550/4885TYK2 3816/4885PDE9A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.